LAPTM4B-35 protein as a potential therapeutic target in gastric cancer.

Tumour Biol

Department of Pathology, The First Affiliated Hospital of Liaoning Medical University, Jingzhou, Liaoning, 121001, People's Republic of China.

Published: December 2014

The objective of this study is to investigate lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) protein expression in gastric cancer and its clinical implications. LAPTM4B-35 protein expression in 652 gastric cancer specimens and matched adjacent non-cancerous tissues was evaluated by immunohistochemical staining. Subsequently, the relationship between LAPTM4B-35 protein expression, clinical pathological parameters, and prognosis of gastric cancer was determined. LAPTM4B-35 protein expression was significantly higher in gastric cancer tissue compared to adjacent non-cancerous tissues (P = 0.001). In total, 417 (63.96 %) of the 652 gastric cancer cases demonstrated high LAPTM4B-35 protein expression. Multiple regression analysis was performed to identify the factors related to lymph node metastasis. As a result, age, tumor number, primary tumor category, histological type, histological growth pattern, and LAPTM4B-35 protein expression were found to be significantly related to lymph node metastasis (P = 0.010, 0.001, 0.032, 0.001, 0.001, and 0.001, respectively). Survival analysis identified that LAPTM4B-35 protein expression was also an independent prognostic factor (P = 0.001). LAPTM4B-35 was highly expressed in gastric cancer and may be a potential target for the management of gastric cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-014-2599-0DOI Listing

Publication Analysis

Top Keywords

laptm4b-35 protein
32
gastric cancer
32
protein expression
28
laptm4b-35
9
gastric
8
cancer
8
protein
8
652 gastric
8
adjacent non-cancerous
8
non-cancerous tissues
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!